Vaccine effectiveness
COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses
Analysis of COVID-19 Vaccination Effectiveness
Reference: Makovec, T., Šorli, A. S., Gorjup, R., Krevel, Z., & Piberl, S. (2023). Analysis of COVID-19 vaccination effectiveness. J Vaccines Vaccin, 14(5), 530. https://doi.org/10.35248/2157-7560.23.14.530 Summary: The article critiques the methodologies used in studies assessing the effectiveness of COVID-19 vaccines. It argues that many published works fail to adhere to the fundamental scientific standard of
COVID-19, Covid-19 vaccines, Genetic vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses
The Complexities of mRNA Vaccines: A Gene Therapy Perspective
Reference: Banoun, H. (2023). mRNA: gene therapy or vaccine? SAVIMS (South Africa Vaccine Injury Medicolegal Study Group). Summary: Hélène Banoun’s article delves into the intricate nature of mRNA vaccines, positioning them within the broader context of gene therapy. She explains the dual role of RNA viruses, particularly coronaviruses, in infecting host cells and highlights the
COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses
Confronting the COVID Vaccine Debate: A Call for Transparency
Reference: Kirsch, S. (2023, March 1). Why is everyone so afraid to talk about the elephant in the room? Steve Kirsch. Substack. https://stevekirsch.substack.com/p/why-is-everyone-so-afraid-to-talk Summary: In his article, Steve Kirsch presents a critical view of the COVID-19 response, arguing that significant errors were made regarding vaccines, masks, social distancing, and lockdowns. He contends that vaccines have
COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses
Effectiveness of the COVID-19 Bivalent Vaccine
Reference: Shrestha, N. K., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A., & Gordon, S. M. (2022). Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine. medRxiv. https://doi.org/10.1101/2022.12.17.22283625 Summary: This study evaluated the effectiveness of the bivalent COVID-19 vaccine among 51,011 employees at the Cleveland Clinic. The results indicated a 30% effectiveness
COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses
Estimation of Number Needed to Vaccinate Against COVID-19 Hospitalisation
Reference: UK Health Security Agency. (2023). Estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group. Retrieved from [URL] Summary: The UK Health Security Agency’s report outlines the calculation of the number needed to
COVID-19, Covid-19 vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses
Rethinking Next-Generation Vaccines for Respiratory Viruses
Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146-157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The article discusses the challenges in developing effective vaccines for respiratory viruses such as SARS-CoV-2 and influenza. These viruses often replicate rapidly in the